BIOSYSEN 01355

BIOSYSEN (01355) Company Profile
返回 Financials Announcements Buybacks Disclosure Cibo Flash
Code01355
Name (EN)BIOSYSEN
BoardMain Board
ISINKYG5458R1175
Amounts are in the company's reporting currency, auto-scaled (K/M/B/T).
Income Statement
Item 20212022202320242025-0620252026-06
Revenue 57.69M56.28M61.32M37.68M25.45M46.34M25.09M
Gross profit 57.69M56.28M61.32M36.97M30.47M
Other income and gains, net 1.26M2.56M977.81K2.15M1.99M
Operating profit 6.5M-7.79M-47.92M-28.89M-36.56M
Net finance costs -6.63M-6.6M-5.25M-5.45M-4.43M2.04M
Profit before tax -122.64K-14.38M-53.17M-34.33M-40.99M
Income tax expense -3.16M-1.38M-2.8M-2.49M
Profit for the year -3.28M-15.76M-55.98M-36.82M-40.99M
Profit attributable to owners 4.07M-6.96M-34.6M-19.56M-13.48M-39.32M21.15M
Balance Sheet
Item 202120222023202420252026-06
Cash and cash equivalents 11.69M2.17M2.01M12.83M2.21M1.09M
Trade and bills receivables 3.91M14.26M970.56K893.63K4.93M
Inventories 309.87K307.28K347.99K372.27K336K
Total current assets 21.64M26.28M8.35M16.48M18.04M
Total assets 196.37M175.23M115.38M69.5M72.66M
Total current liabilities 70.19M81.08M73.77M67.85M78.26M
Total liabilities 197.99M193.88M190.36M167.06M165.6M
Total equity -1.61M-18.65M-74.98M-97.56M-92.94M
Equity attributable to owners 10.08M1.95M-32.94M-39.22M-31.84M
Cash Flow Statement
Item 20212022202320242025
Net cash from operating activities 24.85M8.35M31.86M22.47M-29.53M
Net cash from investing activities -13.33M-2.62M-583.61K-231.51K-28.74M
Net cash from financing activities -16.2M-16.98M-31.67M-11.09M47.86M
Net increase in cash -4.68M-11.25M-387.86K11.15M-10.4M
Source: HKEX public data.
Board of Directors
List as of 2025-10-10
Executive Directors
Non-Executive Directors
Independent Non-Executive Directors
Source: HKEXnews
Corporate Actions
Date Type Ratio Price Amount Summary
2026-09-22 Change in Securities Terms 0.129 HKD 因供股触发可换股债券转换价调整机制，转换价由每股0.155港元调整为0.129港元，追溯自2026年8月4日起生效。
2026-09-07 Rights Issue 2 : 1 0.068 HKD 40M HKD 生物系統工程有限公司按每2股現有股份獲發1股供股股份之基準，以每股0.068港元進行供股，最終發行596,532,580股供股股份，所得款項總額約40,000,000港元，供股及配售事項於2026年9月3日成為無條件。
2026-08-25 Placing 2 : 1 0.068 HKD 生物系統工程有限公司按每2股現有股份獲發1股供股股份的基準，以每股0.068港元供股，發售596,532,580股供股股份，其中340,531,862股獲有效接納，256,000,718股未獲認購並受補償安排規限。
2026-08-25 Capital Reorganisation 股東特別大會通過將法定股本由20,000,000港元（分為2,000,000,000股每股0.01港元）增加至100,000,000港元（分為10,000,000,000股股份）。
// About this page //

This page shows BIOSYSEN (01355) company profile, historical financial statements and board of directors. Financial data comes from public financial disclosures in HKEX display documents, grouped by reporting period; the director roster comes from HKEXnews.

Disclaimer

Site Nature: This website (cibo.hk) is an independent technology product showcase platform established by Panda Securities Limited (“the Company”), dedicated to demonstrating the data analysis capabilities of AI technology products and facilitating research exchange. This website itself and all data analysis content displayed herein do not constitute, and are not involved in, any regulated activity or licensed service requiring approval by the Hong Kong Securities and Futures Commission (“SFC”) under the Securities and Futures Ordinance. Browsing or using the content of this website does not establish any regulated client relationship with the Company.

Not Investment Advice: Any information contained on this website (including but not limited to data analysis charts, statistical results, allotment rate comparisons, etc.) is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, guarantee, or endorsement of any investment product or strategy. The output of this AI analysis tool should not be interpreted as investment opinion.

Decision Responsibility: Users should understand that all investment decisions involve risk. Users should make investment decisions based on their own independent judgment, financial situation, investment objectives, and risk tolerance, and consult independent licensed financial advisors or professional advice when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions or actions made by users based on the information on this website.

Technical Limitations: This AI analysis tool is algorithm-driven and data-based. Its analysis results are limited by model capability, data quality, market conditions, and other factors. Past analysis results are not reliable indicators of future performance. The Company does not guarantee the accuracy, completeness, timeliness, or suitability of the analysis results of this tool. All analysis results are automatically generated by AI algorithms, and have not been manually reviewed or verified by the publisher. Analysis charts, statistical data, and trend assessments may contain errors or biases.

Data Sources: The data on this page is sourced from publicly disclosed documents published by HKEX News and other institutions. The relevant institutions make no warranty regarding the accuracy, timeliness, or completeness of such data, nor do they endorse the analysis conclusions derived from such data.

Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated securities and futures trading services, investment advisory, and other licensed activities provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.

Panda Securities Limited is a licensed corporation regulated by the Hong Kong Securities and Futures Commission (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). The publisher of this website shall not be liable for any direct or indirect losses arising from the use of this website or its analysis results. Use of this website constitutes acceptance of this disclaimer.